Form 4: Neurocrine Biosciences Director Equity Grant

Director Gary A. Lyons received a grant of restricted stock units and stock options from Neurocrine Biosciences.

Summary

• Director Gary A. Lyons was granted 1,284 Restricted Stock Units (RSUs) on May 27, 2026.
• Director Gary A. Lyons was granted 2,624 Non-Qualified Stock Options with an exercise price of $155.83 on May 27, 2026.
• The RSUs are scheduled to vest in full on May 27, 2027.
• The stock options vest in 12 equal monthly installments beginning June 27, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Market volatility affecting the value of equity grants.
• Potential dilution of existing shares upon exercise or vesting of equity awards.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure director retention and alignment with long-term corporate performance.

Comparison to Industry Standards

• The grant structure is consistent with standard compensation packages for non-employee directors in mid-to-large cap biotech firms.
• Vesting schedules for options and RSUs align with typical industry practices for board members.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation event.

Next Steps

• Vesting of stock options beginning June 27, 2026.
• Vesting of RSUs on May 27, 2027.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Trading, Equity Compensation, Director Compensation